U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907251) titled 'Dapagliflozin for Long COVID Syndrome' on March 31.
Brief Summary: This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
COVID - 19
Long COVID Syndrome
Intervention:
DRUG: Dapagliflozin (DAPA)
Dapagliflozin 10mg orally once a day for 12 months
DRUG: Placebo
Participants will receive a matching placebo taken once daily by mouth for 12 months.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ottawa Heart Institute Research Corporation
Published by HT Digital Content Service...